



Investing to Close the Women's Health Gap

Impact Report





Addressing the gap: Solving for gender inequity in health

At Nia, one of our founding principles is to support, uplift, invest in, and celebrate women. We are a women led team of 90% women and 100% feminists. We understand that prioritizing women's health is a critical component of creating a healthy economy. As Dr. Stella Bosire, Founding Director of the Africa Center for Health Systems and Gender Justice notes, "When we invest in keeping women healthy, we unlock women's economic power."¹

When we invest in keeping women healthy, we unlock women's economic power.

-Dr. Stella Bosire

When it comes to research, investment and direct care, closing the women's health gap could boost the global economy by at least \$1 trillion per year by 2040. Nia actively seeks to invest in companies addressing this gap in research, as well as those working to reduce barriers for care delivery.²

Women spend 25% more of their lives than men do experiencing debilitating health conditions, resulting in losses for our economy and our communities.³ Through our investment approach we aim to promote access to quality healthcare, preventative care, and protections for reproductive rights for women.



¹ Bosire, S, et. al. (2023, July 17). [The link between women's health and women's economic power](#). *Bill and Melinda Gates Foundation*.

² Ellingrud, K, et. al. (2024, January 17). [Closing the Women's Health Gap: A \\$1 Trillion Opportunity to Improve Lives and Economies](#). *World Economic Forum*.

³ Whiting, K. (2024, February 27). [5 Conditions that highlight the women's health gap](#). *World Economic Forum*.



An investment in the future

With recent efforts to drastically reduce and even remove reproductive rights, now more than ever, we need to invest in companies that are working to improve the lives of women.



Photo Courtesy of The White House

Investing in women's health is an investment in the future of American families and the economy.

-President Biden

Here we highlight companies in the **Nia Global Solutions portfolio** with services or products directly aiming to improve the health of women, and that have taken extra measures via community projects to address the disparities in women's health. These Nia portfolio companies are collecting data, developing medications and technology solutions, expanding access to healthcare, and working to rebuild trust between BIPOC communities and the medical industry.



Jersey City, New Jersey

Organon leads in addressing unmet medical needs and expanding access to quality medical care for women.⁴ Products include solutions for women facing fertility challenges, such as an injection pen to support ovaries to produce more mature eggs,⁵ and fertility medicine to prevent premature ovulation in women undergoing fertility treatment.⁶ Organon also provides birth control products, including a vaginal ring and an arm implant that uses a hormone to prevent eggs from being released from the ovary. Other efforts include providing control and treatment of abnormal postpartum hemorrhaging, a vaginal gel to treat bacterial vaginal infections, medication to treat or prevent osteoporosis in women after menopause,⁷ and medication for the treatment of HER2+ breast cancer.⁸

In 2023, Organon launched Her Plan is Her Power, a three-year initiative with \$30M pledged toward reducing unplanned pregnancies.

Organon also works to improve women's health on a global scale. In 2023, they launched Her Plan is Her Power, an initiative with \$30M pledged in grants toward reducing unplanned pregnancies. In countries such as the Dominican Republic, South Korea, Germany, and Thailand, Organon is providing resources to help women and girls reduce unplanned pregnancies and take control of their reproductive health. Organon has also issued grants tailored to the needs of women and girl refugees in Ukraine and Poland.⁹



Photo Courtesy of Hologic

Important Information: As of 3/18/2024, these securities represented the following percentages of the Nia Global Solutions portfolio: Organon & Co. (0.96%), Daiichi Sankyo Company (1.60%), Hologic Inc. 2.03%

⁴ [2022 ESG Report Highlights](#). (FY 2022). *Organon*. ⁵ [Patient Information Follistim Cartridge](#). (2024, February). *Organon*.

⁶ [Ganirelix Acetate Injection](#). (2024, February). *Organon*. ⁷ [Medication Guide Fosamax](#). (2021, June). *Organon*.

⁸ [What conditions is Ontruzant used to treat \(indications\)?](#) (2021). *Ontruzant*. ⁹ [2022 ESG Report Highlights](#). (FY 2022). *Organon*.



ORGANON

Jersey City, New Jersey

In 2022, Organon launched the Her Promise Access Initiative in collaboration with other global organizations to expand contraception availability to the 73 lowest-income countries. 47 million women have been given access to the Organon birth control implant to prevent 57 million unintended pregnancies. Organon is using artificial intelligence to provide information and analytics about sexual and reproductive health to frontline healthcare workers in low-resource settings. Also in 2022, Organon partnered with the New Jersey Birth Equity Funding Alliance (NJBEFA) to reduce maternal mortality in New Jersey and eliminate racial disparities in birth outcomes. In the United States, Organon's Patient Assistance Program (PAP) provides certain products free of charge for patients in need of financial support.¹⁰

Organon's Current Research Priorities¹¹

- Breast cancer**
- Osteoporosis**
- Preterm labor**
- Endometriosis pain**
- Bacterial vaginosis**
- Hormone-free, on-demand contraception**
- Postpartum hemorrhage**
- Improving hysterectomy procedures**




Photo Courtesy of NYSE

Important Information: As of 3/18/2024, these securities represented the following percentages of the Nia Global Solutions portfolio: Organon & Co. (0.96%), Daiichi Sankyo Company (1.60%), Hologic Inc. 2.03%

¹⁰ 2022 ESG Report Highlights. (FY 2022). Organon.

¹¹ Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy. (2023, January 5). Organon.



HOLOGIC®

Marlborough, Massachusetts

Hologic is a medical technology company working to advance women’s health. Hologic produces 29 products for breast health, 19 for gynecological health, 6 for sexual health, and 2 for skeletal health. Hologic understands that *for our world to thrive, women’s health must be prioritized*. In 2019, in partnership with Gallup, they launched the Hologic Global Women’s Health Index, a global measure to track progress in key aspects of women’s health and well-being, with plans to extend the life expectancy of women and improve their quality of life.¹² This data effort contributes to the World Economic Forum’s Women’s Health Initiative, which supports global efforts to protect women’s and girl’s reproductive and maternal health.¹³



Photo Courtesy of Hologic

In **Taiwan** and **Thailand**, Hologic provides mammography machines to mobile clinics for health check-ups at little to no cost to women in remote areas.

In **Costa Rica**, Hologic provides grants, food and other resources to a nonprofit hostel offering free lodging, food, and basic health services to women seeking breast cancer treatment.

In **Rwanda**, Hologic supports an organization made up of breast cancer survivors conducting outreach to educate women on the importance of breast health.

In **Kenya**, Hologic supports an organization increasing screening programs for breast cancer, cervical cancer and sexually transmitted infections and expanding education efforts to lower the rate of teenage pregnancy.

Hologic participates in several grassroots efforts to provide care for underserved and unserved communities. Stateside, Hologic supports women’s health through Project Health Equality, to provide underserved residents with access to screenings for cervical and breast cancer and working on research to reduce health disparities and to better understand the impacts of messaging around race, ethnicity, and gender in healthcare. In San Diego, CA, Hologic provides grants to community clinics facilitating access to preventative care for women in under-resourced communities.¹⁴

As of 3/18/2024, these securities represented the following percentages of the Nia Global Solutions portfolio: Organon & Co. (0.96%), Daiichi Sankyo Company (1.60%), Hologic Inc. 2.03%

¹² [The Hologic Global Women’s Health Index](#), (2024). Hologic, Inc.

¹³ [2022 Sustainability Report](#), (2022). Hologic, Inc.

¹⁴ [2022 Sustainability Report](#), (2022). Hologic, Inc.



Tokyo, Japan

Daiichi Sankyo is a drug discovery and delivery company that produces medication for the treatment of unresectable or metastatic HER2 positive breast cancer. Daiichi also develops medications to address Iron Deficiency Anemia (IDA) which disproportionately affects women and girls due to menstrual and pregnancy-related iron loss.¹⁵ Daiichi Sankyo produces medications to treat osteoporosis, a medical condition that women are more prone to experience as an effect of menopause.¹⁶

Beyond creating products to improve women's health, Daiichi Sankyo has undertaken several projects to expand access to healthcare and education to advance women's healthcare.



Photo Courtesy of Daiichi Sankyo

In partnership with Américas Amigas, Daiichi Sankyo launched the Mulheres Amigas - Temporada Amazônia initiative, which focused on providing women in the **Amazon** with free breast cancer screenings via a mammography truck. The mobile service reached six cities in the Amazon, assisting 4,742 women with exams and consultations.¹⁷

In **Myanmar**, Daiichi Sankyo collaborated with Plan International to improve mother-child health in rural villages. The project provided mobile healthcare clinics, training for healthcare professionals and volunteers, and health education for mothers.¹⁸

In **Zimbabwe**, Daiichi Sankyo and Plan International collaborated to strengthen healthcare services related to sexual reproductive health and rights, and breast and cervical cancers, where cervical and breast cancers are the leading causes of cancer deaths among women.¹⁹

As of 3/18/2024, these securities represented the following percentages of the Nia Global Solutions portfolio: Organon & Co. (0.96%), Daiichi Sankyo Company (1.60%), Hologic Inc. 2.03%

¹⁵ [Iron deficiency and anaemia in women and girls](#). (2023.) *International Federation of Gynecology and Obstetrics*.

¹⁶ [Osteoporosis](#). (2021, February 22). *U.S. Department of Health & Human Services*.

¹⁷ [Daiichi Sankyo Brasil's Amazon Region Breast Cancer Screening Initiative, Part 2—the Results](#). (2023, September 25). *Daiichi Sankyo*.

¹⁸ [Working with the people of Myanmar: Creating communities that support safe and healthy childbirth and childcare](#). (2020, October 9). *Daiichi Sankyo*.

¹⁹ [Public Awareness Activities and Strengthening of Healthcare Infrastructure for SRHR and Breast and Cervical Cancers in Zimbabwe](#). (2021). *Daiichi Sankyo*.



IMPACT CAPITAL

(510) 319-9221

info@niaimpactcapital.com

Proudly investing and engaging
from Oakland, California

This document is for informational purposes to illustrate Nia's commitment to women's health. This presentation is not intended to be construed as legal, tax or investment advice and does not constitute an offer to sell or the solicitation of any offer to buy any security. Any mention of an individual security is for illustrative purposes only and is not to be considered a recommendation to buy or sell a security. Investors are strongly advised to seek professional advice before making any investment decisions. All investing involves risk, including the possible loss of principal. Past performance is no guarantee of future results.

The companies identified in this piece (Invest in Women's Health Impact Report) were selected based upon the following criteria: (i) For each of these companies, women's health products are the key drivers of revenue and constitute the biggest segment by revenue. (ii) the companies are held by the Nia Global Solutions portfolio as of the date of this document, and (iii) in our opinion, the companies exhibit exemplary efforts to expand access to women's healthcare beyond the scope of their normal business activities. The specific securities identified and described therein do not represent all securities purchased, sold, or recommended for the Nia Global Solutions portfolio. We do not suggest that investments in the securities identified and discussed were or will be profitable. The incorporation of environmental, social, and governance ("ESG") considerations into the investment process may cause the investment adviser to make different investments than other funds that have similar investment portfolios and/or investment styles. Under certain economic conditions this could cause the investment adviser's performance for any of its portfolios, including the Portfolio, to be better or worse than similar portfolios that do not incorporate such considerations into their investment strategies or processes. In applying ESG criteria to its investment decisions, the investment adviser may forgo higher yielding investments that it would invest in absent the application of ESG investing criteria.